Trial Profile
A multi-center, randomized, phase 3 study of iodine I 131 tositumomab therapeutic regimen versus ibritumomab tiuxetan therapeutic regimen for patients with relapsed or transformed follicular non-Hodgkin's lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Ibritumomab tiuxetan
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 27 Jan 2007 Status change
- 01 Oct 2005 New trial record.